A clinician sees a pattern in their own patients. They run the numbers to check it, and the numbers seem to confirm what they already suspected. But that confirmation might not be real. “Often a clinician at the point of care will come to us with a hunch — ‘I’ve seen a bunch of these…
ADA conference roundup: GLP-1 trial results and researchers removed by police
Eli Lilly, Novo Nordisk, AstraZeneca and more announced recent GLP-1 clinical and preclinical data at the American Diabetes Association’s (ADA’s) national conference this week. The conference was eventful, with several experts being escorted out by police after handing out copies of an editorial criticizing the Trump administration’s science policies. The editorial was published in the…
Boehringer Ingelheim eyes MASH as the next front for survodutide, a GLP-1/glucagon receptor dual agonist
For decades, fatty liver disease and its more serious inflammatory form, metabolic dysfunction-associated steatohepatitis (MASH), were often overlooked conditions with few approved treatments. Boehringer Ingelheim is among the companies now going after them with a concerted push. “We have a program in MASH, in the liver, the LIVERAGE program, plus a robust data-generation program to…
Lilly’s triple agonist achieves 16.8% weight loss in phase 3 trial
Eli Lilly’s triple agonist, retatrutide, demonstrated an average weight loss of 16.8% in a Phase 3 trial for the treatment of type 2 diabetes, the company announced today. Retatrutide is an investigational first-in-class GIP, GLP-1 and glucagon triple hormone receptor agonist. The drug met the primary and key secondary endpoints, delivering superior A1C reduction and…
Novo Alzheimer’s trial disappoints as amycretin shines
On Monday, Novo Nordisk announced that the results from its Phase 3 trial investigating semaglutide as a treatment for Alzheimer’s “did not confirm the superiority of semaglutide versus placebo in the reduction of progression,” of the disease, according to the press release. Monday’s announcement had a silver lining. That is, the treatment did result in…
Lilly’s tirzepatide cuts diabetes risk by 94% in those facing obesity
Eli Lilly’s hit drug tirzepatide has demonstrated a 94% reduction in the risk of developing type 2 diabetes among overweight and obese prediabetic adults, according to new findings from a 176-week Phase 3 trial. The SURMOUNT-1 study, the longest completed trial of tirzepatide to date, also showed sustained weight loss through the treatment period, with…
Teva readies first generic version of GLP-1 drug Victoza in U.S.
Generic giant Teva Pharmaceuticals will launch the first generic version of Victoza (liraglutide injection 1.8mg) in the U.S, making it the first generic GLP-1 drug to enter the U.S. market. The patent for Novo Nordisk–developed liraglutide is set to expire until November 18, 2024. Other popular GLP-1 drugs, such as semaglutide (marketed as Ozempic and…
GLP-1s overtake metformin in metabolic clinical trials by a wide margin: A visual exploration
A recent review of more than 2,000 studies related at least indirectly to obesity on clinicaltrials.gov highlights the pronounced significant shift in research focus toward GLP-1 receptor agonists for a range of indications with at least some involvement of metabolic disorders. The site, which provides a robust but not-exhaustive snapshot of clinical trial activity, cites…
Why Lilly’s tirzepatide has blockbuster potential
Tirzepatide from Eli Lilly (NYSE:LLY) continues to show promise for diabetes, outperforming popular diabetes drugs in head-to-head clinical trials, according to GlobalData. In the recent SURPASS-4 study, tirzepatide supported the reduction of hemoglobin A1C (HbA1c) in people with type 2 diabetes while also supporting weight loss. The study pitted tirzepatide against insulin glargine. Tirzepatide is a dual glucose-dependent insulinotropic…